Impact of drug substitution on cost of care: an example of economic analysis of cetuximab versus panitumumab.
Yifan XuJoel W HayAfsaneh BarziPublished in: Cost effectiveness and resource allocation : C/E (2018)
Panitumumab can lower the cost of care without impacting outcomes in chemo-refractory mCRC settings. This finding provides a strong argument to consider panitumumab in lieu of cetuximab in these patients.
Keyphrases
- metastatic colorectal cancer
- wild type
- healthcare
- end stage renal disease
- palliative care
- quality improvement
- newly diagnosed
- ejection fraction
- locally advanced
- chronic kidney disease
- photodynamic therapy
- prognostic factors
- type diabetes
- metabolic syndrome
- emergency department
- affordable care act
- adipose tissue
- squamous cell carcinoma
- radiation therapy
- skeletal muscle
- chronic pain
- health insurance